Akari Therapeutics Plc · NASDAQ:AKTX
Akari Therapeutics — Investor Presentation (August 2026)
30 slides from Akari Therapeutics's investor presentation, August 2026
Slide 1: Advancing Antibody Drug Conjugates with Novel Payloads Targeting RNA Splicing
Corporate Presentation Advancing Antibody Drug Conjugates with August 2026 Novel Payloads Targeting RNA Splicing NASDAQ: AKTX akaritx.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes expressed or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), about the Akari Therapeutics, Plc
Slide 3: Driving Novel ADC Payload Innovation To Address Market Needs and Create Near-Term Value
Akari: Driving Novel ADC Payload Innovation To Address Market Needs and Create Near-Term Value Acceleration 1 2 3 ADC Payload Internal Development Near-Term Value Innovation - AKTX-101: TROP2; IND enabling activities, Phase 1 mid-2027 - AKTX 101: Near term IND/Phase 1 trial - Urgent need for new pay
Slide 4: PH1 Payload Powers a Growing ADC Pipeline
PH1 Payload Powers a Growing ADC Pipeline Lead Asset AKTX-101 in IND-Enabling Studies; Phase 1 Initiation Targeted by Mid-2027 ADC Programs Indication Discovery Preclinical IND Enabling Highlights (All PH1 Payload Based) - Initiated IND enabling activities - GLP tox data expected Q4 2026 Urothelial
Slide 5: AKTX-101 Path to Clinic: Projected Phase 1 Initiation By Mid-2027
AKTX-101 Path to Clinic: Projected Phase 1 Initiation By Mid-2027 Activity 2026 2027 IND / CTA Supportive Preclinical Enabling Activities GLP Toxicology CMC Scale Up Studies (Preclinical) IND/CTA Pre-IND Filing FIH Start - Timeline Consultation (IND / CTA) Dose Escalation Strategic Partnership KRAS
Slide 6: The Next Wave of ADC Innovation Will Be Driven by Novel Payloads
The Next Wave of ADC Innovation Will Be Driven by Novel Payloads 6
Slide 7: ADCs Have Transformed Cancer Treatment And Continue To Drive Significant R&D Investment and Deal Flow
ADCs Have Transformed Cancer Treatment And Continue To Drive Significant R&D Investment and Deal Flow Clinical success, commercial adoption and unprecedented investment have established ADCs as a cornerstone of oncology therapeutics Commercial ADC Success Has Been Built 17 on Two Dominant Payload Cl
Slide 8: Recent ADC Deal Flow Highlights Strong Pharma Demand
Recent ADC Deal Flow Highlights Strong Pharma Demand for Next- Generation ADC Technologies To Further Accelerate Category Recent Landmark ADC Transactions $1.5 Billion $5 Billion $2.5 Billion Up to Up to acquired by acquired by acquired by July 6, 2026 April 7, 2026 March 6, 2026 Underscored by Nume
Slide 9: Relapsed Patients Have No Options for ADC Sequencing Due to Lack of Novel Payloads
Despite ADC Successes in Earlier Lines of Therapy, Relapsed Patients Have No Options for ADC Sequencing Due to Lack of Novel Payloads Sequential Use of ADCs With Same Payload Class Have Significantly Less Efficacy Vs. Prior Line of ADC Therapy Breast Cancer Enhertu® DESTINY Breast062 SATEEN Study Re
Slide 10: Akari's PH1 ADC Payload Can Solve For This Sequencing Issue
Akari’s PH1 ADC Payload Can Solve For This Sequencing Issue: Targeting RNA Splicing To Drive Differentiated Efficacy and Safety PH1: A Differentiated ADC Payload Designed to Expand Therapeutic Potential of ADCs Novel Mechanism of Action Potent Cytotoxic Activity Disrupts RNA splicing, depleting RNAs
Slide 11: PH1 Targets the SF3B1 Spliceosome Complex to Disrupt RNA Splicing
PH1 Targets the SF3B1 Spliceosome Complex to Disrupt RNA Splicing and Drive Cancer Cell Death Primary Driver of Cytotoxicity Potential Immune Benefit Depletion of essential proteins resulting from splicing Mis-spliced proteins may generate neoantigens that can disruption drives potent and broad cyto
Slide 12: PH1 Selectively Targets the SF3B1 Spliceosome Complex
PH1 Selectively Targets the SF3B1 Spliceosome Complex PH1 is novel and proprietary 3rd generation Thailanstatin Analog With Differentiated Binding/Functionality Model of SF3B1 and PHF5α binding to intron BPA and Binding to SF3B1 disrupts normal spliceosome function location of resistance mutations a
Slide 13: PH1 Induces Broad RNA Mis-Splicing: Cytotoxicity And Neoantigen Generation
PH1 Induces Broad RNA Mis-Splicing: Drives Both Cytotoxicity And Generation of Neoantigens To Activate the Immune System PH1 Generates ~9× More Potential Neoantigen-Generating RNA Transcripts Than DM4 payload (Microtubule Inhibitor) Average (n=4 wells) expression of spliced RNA transcripts showing e
Slide 14: PH1 Combines Potent Cytotoxicity with a Differentiated Therapeutic Profile
PH1 Combines Potent Cytotoxicity with a Differentiated Therapeutic Profile Attribute PH1 Payload Topo1 Inhibitors Microtubule Inhibitors Optimal Potency as a < 5 nanomolar IC50 5-20x nanomolar IC50 < 1 nanomolar IC50 Cytotoxic Agent Susceptible to MDR No – payload not subject to this tumor Yes – Cre
Slide 15: PH1 Payload Demonstrates Potent Cytotoxicity Vs. Microtubule Inhibitor Payload
PH1 Payload Demonstrates Potent Cytotoxicity Vs. Highly Potent Microtubule Inhibitor Payload: Cellular Toxicity Trastuzumab PH1 vs. Kadcyla in Her2High NCI-N87 Model Trastuzumab conjugated ADC termed Tras PH1 exhibited durable anti-tumor efficacy in NCI-N87 xenograft tumors vs. Kadcyla (microtubule
Slide 16: PH1 Payload's Immunotherapy Mode of Action Drives Complete Remission and Immunological Memory
PH1 Payload’s Immunotherapy Mode of Action Uniquely Drives Complete Remission and Immunological Memory Against Tumor Anti-Tumor Immunity PART 1: PART 2: Potent Activity of PH1 ADC As Single Agent PH1 Payload Induces Tumor-Specific and With Checkpoint Inhibitor Immunological Memory Against Cancer Cel
Slide 17: Trastuzumab PH1 Durable Remissions Driven By Innate and Adaptive Immune System
Trastuzumab PH1 Durable Remissions Are Driven By Activating Both Innate and Adaptive Immune System – Unlike Other ADC Payloads Tras-PH1(1) Immune Mode of Action Driven By Unique Innate and Adaptive Immune Response Increase in Pro-Inflammatory Macrophages and Neutrophils for Tras-PH1 vs Kadcyla® Expa
Slide 18: PH1 Payload Designed to Overcome Traditional Resistance Mechanisms
PH1 potency unaffected by overexpression of PH1 Payload Designed to Overcome multidrug resistance (MDR) transporters Traditional Resistance Mechanisms 120 100 Experienced by Currently Approved or in % Live Cells 80 Development ADC Payloads 60 MES-SA MES-SA/MX2 40 PH1 MES-SA/MX2 + Elacridar 20 0 0.00
Slide 19: Lead Program AKTX-101 (TROP2 PH1 ADC)
Lead Program AKTX-101 (TROP2 PH1 ADC) Initially Targeting Urothelial Cancer 19
Slide 20: AKTX-101: Highly Differentiated TROP2 ADC With Novel PH1 Payload
AKTX-101: Highly Differentiated TROP2 ADC With Novel PH1 Payload Novel Antibody With Cell Killing Intact - Employs proprietary TROP2 antibody - Higher affinity than hRS7 (Sacituzumab) - Potent ADC action while mitigating ADA immunogenicity Reduced Off-Target Effects - AKTX-101 uses L22 lysine non- c
Slide 21: AKTX-101 Demonstrates Superior Tumor Regression Compared To Trodelvy
AKTX-101 Demonstrates Superior Tumor Regression At Significantly Lower Dose/DAR Compared To Trodelvy® (Topo1 ADC) Tumor Volume (mm3) 750 Method NCI-N87 cell xenograft model Dosing regimen: Day 1 and Day 8 for both 500 AKTX-101 and Trodelvy® to align with approved dosing schedule for Trodelvy® Result
Slide 22: AKTX-101 Has Demonstrated Significant Activity In Aggressive Urothelial Cancer Preclinical Model
AKTX-101 Has Demonstrated Significant Activity In Aggressive Urothelial Cancer Preclinical Model MB49-hTrop2 Bladder ModelMB49-h Model Trop-2Urothelial MB49-hTrop-2 UrothelialCancer Trop2 PH1 doses Cancer 3000 mPD-1 Last Day Tumor Volume (mm3) of Dosing Vehicle Murine anti-PD1 P value (Day mPD-1 ant
Slide 23: AKTX-101 Has a Differentiated Safety Profile vs Current TROP2 ADCs
AKTX-101 Has a Differentiated Safety Profile vs Current TROP2 ADCs: No Neutropenia, Diarrhea, Mucositis or Interstitial Lung Disease Observed Key Safety Warnings of Approved TROP2 ADCs - Boxed warning for neutropenia or bone marrow suppression (Trodelvy®) - GI toxicities (Trodelvy®) - Lung toxicity
Slide 24: In Urothelial Cancer, 2nd Line Opportunity is an Attractive Strategic Entry Point
In Urothelial Cancer, 2nd Line Opportunity is Valuable and Makes an Attractive Strategic Entry Point for AKTX-101 DIAGNOSIS: metastatic Urothelial Carcinoma (mUC) PREFERRED 1ST LINE THERAPY (Standard of Care for All-Comers) + Enfortumab Vedotin + Pembrolizumab (Regardless of Cisplatin Eligibility) D
Slide 25: Urothelial Cancer is Part of a Larger Opportunity for AKTX-101
Urothelial Cancer is Part of a Larger Opportunity for AKTX-101, Based on Solid Tumors That Have High TROP2 Expression Cancer Type New Annual Cases Annual Deaths Initial Target: Urothelial 85,000 17,000 Breast 319,750 42,680 Lung 226,650 124,730 Colorectal 154,270 52,900 Head and Neck 72,680 16,680 P
Slide 26: First-in-Human Phase 1a Trial Design and Phase 1b Expansion
First-in-Human Phase 1a Trial Explores Safety, Therapeutic Dose and Identifies Efficacy Signals in Range of Solid Tumors Phase 1b Expansion into Urothelial Cancer Drives Potential Accelerated Path First-in-Human Phase 1a Trial Explores Safety, Therapeutic Dose and Identifies Efficacy Signals in Rang
Slide 27: Partnerships Are Accelerating The Development and Value of PH1 ADC Payload
Partnerships Are Accelerating The Development and Value of PH1 ADC Payload 27
Slide 28: Akari Has Entered Into Two Strategic Partnerships To Advance the PH1 Payload
Akari Has Entered Into Two Strategic Partnerships To Advance the PH1 Payload Through Multiple Ways: Internal Pipeline And Dual Payload ADCs Independent Collaborations Spanning Manufacturing Scale-Up and Dual-Payload Discovery Development & Manufacturing Partnership Dual-Payload Research Collaboratio
Slide 29: Akari is Positioned to Lead the Next Generation of ADC Payload Innovation
Akari is Positioned to Lead the Next Generation of ADC Payload Innovation Differentiated Payload Platform Key Target Milestones • First-in-class ADC payload targeting RNA splicing to attack cancer The Next 18 Months • PH1 is a potent cytotoxic and immuno-therapeutic as a single agent • Designed to c
Slide 30: Supplemental Corporate Information
Supplemental Corporate Information: Akari Website: https://akaritx.com Recent Press Releases: 1. Akari Therapeutics Secures Australian Patent Approval 2. ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors 3. Akari Therapeutics Announces Strategic Partnership w
Akari Therapeutics — Investor Presentation (August 2026) on 6ix